PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2023-06-16 (3)

Date Title Company
16-Jun-2023 FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Businesswire